Overview

Cannabidiol in Sickle Cell Disease

Status:
RECRUITING

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

Phase:

PHASE1

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Treatments:

Cannabidiol